Ironwood Pharmaceuticals, Inc. (IRWD)
After hours:
| Previous close | 7.88 |
| Open | 7.84 |
| Bid | 7.72 x 2000 |
| Ask | 7.75 x 1800 |
| Day's range | 7.72 - 7.95 |
| 52-week range | 7.53 - 15.70 |
| Volume | |
| Avg. volume | 4,555,485 |
| Market cap | 1.232B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.45 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
Business WireIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
BOSTON, April 25, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 3416473. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodp
ZacksOPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
Investor's Business DailyIronwood Pharmaceuticals Ran Up 38% Over Three Months — And Just Lost It All
Shares of Ironwood Pharmaceuticals collapsed Thursday on mixed results for its gastrointestinal drug. The biotech stock erased a 38% gain.
